Please select the option that best describes you:
Topics:
Radiation Oncology • ASTRO 2022
What are your top takeaways from ASTRO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
Answer from: Radiation Oncologist at Community Practice
1. NRG RTOG 1005: A Phase III Trial of Hypofractionated Whole Breast Irradiation with Concurrent Boost vs. Conventional Whole Breast Irradiation Plus Sequential Boost Following Lumpectomy for High Risk Early-Stage Breast Cancer
The results showed that with hypofractionation and SIB technique, 7 yea...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
1. RTOG 1005 - In a large phase 3 trial, demonstrated the safety and efficacy of simultaneous integrated boost in the management of early stage practice. The question that emerges is who to offer this approach to.
2. Long-Term Outcomes of SABR to Primary Renal Cell Carcinoma: A Multicenter Analysis...
Answer from: Radiation Oncologist at Academic Institution
1. NRG/RTOG 1112: It is a phase III study of sorafenib vs. SBRT followed by sorafenib in locally advanced HCC. This study showed the addition of SBRT improved overall survival (OS), progression-free survival (PFS), Time to progression (TTP) without increased toxicity in this patient population. This...
Answer from: Radiation Oncologist at Academic Institution
1. NRG/RTOG-1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma. The results of this long-awaited trial led by Dr. @Laura Dawson showed the benefit of adding SBRT to sorafenib in patients with locally advanced ...
Answer from: Radiation Oncologist at Community Practice
1. LUSTRE (presented by Dr. @Anand Swaminath) - randomized trial of SBRT (48 Gy in 4 fractions for peripheral versus 60 Gy in 8 fractions from central) vs. hypofractionated RT (60 Gy in 15 fractions) for stage I NSCLC. Local control at 3 years was numerically higher for SBRT (88% vs. 81%), though th...
Answer from: Radiation Oncologist at Academic Institution
There were many interesting things presented at ASTRO this year. I have chosen the most important abstract for our near-term practice in treating breast cancer patients and two others that are quite novel but which will need much more study before considering whether to adopt them.
1. Abstract 1: V...
Answer from: Radiation Oncologist at Academic Institution
The issue of using IMPT vs. IMRT in HNC is contentious, with retrospective data suggesting likely similar tumor control but conflicting data regarding the potential clinical superiority of IMPT in reducing acute and late sequellae. While some publications suggest DVH-based superiority of IMPT regard...
Answer from: Radiation Oncologist at Community Practice
Good presentations